Clinical Trial

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC. The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-15
Trial Details
NCT Number NCT07564232
Lead Sponsor M.D. Anderson Cancer Center
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 40 participants
Start Date 2026-07-02
Primary Completion 2031-06-06 (estimated)
Study Completion 2033-06-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-29